
Maridebart cafraglutide showed promising results for weight management in obesity and type 2 diabetes (T2D), achieving significant weight loss without plateau.
Maridebart cafraglutide showed promising results for weight management in obesity and type 2 diabetes (T2D), achieving significant weight loss without plateau.
Since the most recent guidelines were published, more evidence has emerged regarding intravenous corticosteroids for severely ill patients.
New research shows effective interventions can reduce prescriptions across all ages.
An adjusted analysis of the ALPINE and ASCEND trials revealed a statistically significant progression-free survival advantage for zanubrutinib.
Influenza Vaccination Preparation Should Be on the Docket for Any Pharmacy After a Much-Anticipated ACIP Meeting
Statins such as simvastatin do not have additional antidepressive effects in combination with standard escitalopram treatment in patients with comorbid major depressive disorder (MDD) and obesity.
The biosimilar showed similar efficacy, pharmacokinetics, pharmacodynamics, safety, quality of life, and immunogenicity in patients with chronic spontaneous urticaria (CSU).
The data highlight novel therapies and biomarkers shaping personalized cancer care.
New research highlights the benefits of early oseltamivir treatment for hospitalized patients with influenza, reducing mortality and readmission rates while optimizing care.
The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.
Obesity and type 2 diabetes in youth significantly increase the risk of osteoporosis and fractures, highlighting the need for early intervention and healthy habits.
Receiving a COVID-19 vaccination vastly reduced the risk of long-term hospitalization, necessitating dialysis, and morbidity in patients hospitalized with acute kidney injury related to SARS-CoV-2 infection.
The agent, Kirsty, represents a more affordable alternative to Novolog.
Adam James, PharmD, and Chris Altman, PharmD, discuss renewed public scrutiny of thimerosal, its limited use in vaccines today, and how new guidance may affect pharmacists and patient confidence moving forward.
The data showed patients with relapsed or refractory multiple myeloma achieved a 73% overall response rate.
Patients with chronic kidney disease (CKD) were more likely to get vaccinated for influenza and pneumococcal following a health care provider’s recommendation.
Researchers unveil compounds that enhance cell death and boost antiviral responses, offering hope against RSV and other viral infections.
Finerenone emerges as a promising treatment for patients with diabetes and chronic kidney disease, significantly reducing cardiovascular and renal risks.
Millions of seniors and Medicare beneficiaries managing chronic conditions have new options for medication delivery and adherence support.
The fibroblast growth factor receptor 2b (FGFR2b)-inhibiting bemarituzumab demonstrated improvements in overall survival and other key secondary end points compared with placebo in first-line gastric cancer.
Dave’s Pharmacy in Alliance, Nebraska, was named the Pharmacy of the Year for cutting-edge patient care.
Independent pharmacy owners Raj Chhadua and Marc Ost are turning to AI-powered tools to streamline operations, improve efficiency, and enhance patient engagement—without sacrificing the personal touch.
Combination therapy with trastuzumab emtansine and trastuzumab significantly enhances survival rates in HER2-positive early breast cancer, outperforming trastuzumab alone.
From vaccine drives and prescriber dinners to YouTube education and automated workflows, these pharmacy owners are finding innovative, hands-on ways to expand services, boost revenue, and stay connected to the communities they serve.
The expanded instructions for use labeling expand on the Farawave and Farawave Nav Pulsed Field Ablation (PFA) catheters.
Debra Patt, MD, PhD, MBA; and Houston Holmes, MD, discuss the ramifications of the FDA's removal of REMS requirements for approved chimeric antigen receptor (CAR) T-cell (CAR T) therapies.
Arkansas' "shot heard round the pharmacy world": Preventing pharmacy benefit managers from owning pharmacies raises an interesting question for the field.
BCPPs can address behavioral health workforce shortages and advocate for expanded access and reimbursement amid evolving legislation and treatment landscapes.
This designation is significant because there are no FDA-approved treatments for transplant recipients with or preventing antibody-mediated rejection (AMR).